ОБЗОР
МЕЖДУНАРОДНЫХ
ПЕРИОДИЧЕСКИХ
ИЗДАНИЙ

НОВОСТИ СВЕЖИЙ НОМЕР ОБ ИЗДАНИИ
Для специалистов по репродуктивному здоровью. PROdigest. Приложение к бюллетеню
prodigest prodigest prodigest prodigest prodigest
2015 vol1 2015 vol2 2015 vol3 2016 2017

Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.

Authors: Lian Y, Yin H, Pollak MN, Carrier S, Platt RW, Suissa S, Azoulay L.
Publication date: 20170117
Journal: Eur Urol. 2016 Nov;70(5):808-815. Epub 2016 May 10.
DOI: 10.1016/j.eururo.2016.04.035

BACKGROUND:

The association between phosphodiesterase type 5 inhibitors (PDE5-Is), drugs used in the treatment of erectile dysfunction (ED), and melanoma skin cancer is controversial.

OBJECTIVE:

To assess whether the use of PDE5-Is is associated with an increased risk of melanoma skin cancer.

DESIGN, SETTING, AND PARTICIPANTS:

Using the UK Clinical Practice Research Datalink, we assembled a cohort of men newly diagnosed with ED between 1998 and 2014 and followed until 2015. PDE5-I exposure was considered as a time-varying variable lagged by 1 yr for latency purposes.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:

Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of incident melanoma associated with PDE5-I use overall and by number of prescriptions and pills received. Identical analyses were conducted for basal and squamous cell carcinoma, two cancers for which PDE5-related pathways are not thought to be involved.

RESULTS AND LIMITATIONS:

The cohort included 142 983 patients, of whom 440 were newly diagnosed with melanoma during follow-up (rate: 63.0 per 100 000 person-years). Compared with nonuse, PDE5-I use was not associated with an overall increased risk of melanoma (rates: 66.7 vs 54.1 per 100 000 person-years; HR: 1.18; 95% CI, 0.95-1.47). The risk was significantly increased among those who had received seven or more prescriptions and ≥25 pills (HR: 1.30 [95% CI, 1.01-1.69] and 1.34 [95% CI, 1.04-1.72], respectively). In contrast, there was no overall association with basal and squamous cell carcinoma, with an unclear association with numbers of prescriptions and pills received.

CONCLUSIONS:

The use of PDE5-Is was not associated with an overall increased risk of melanoma skin cancer. The increased risks observed in the highest prescription and pill categories require further validation.

PATIENT SUMMARY:

In this study, the use of phosphodiesterase type 5 inhibitors was not associated with an increased risk of melanoma skin cancer.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.